CM
COGT icon

Castleark Management’s Cogent Biosciences COGT Stock Holding History

Castleark Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Buy
+63,950
New +$2.36M 0.08% 192

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Castleark Management's COGT Position: Q1 2026 in Review

Castleark Management opened a new position in Cogent Biosciences (COGT) in Q1 2026: 63,950 shares worth $2.46M. The stake represents 0.08% of the portfolio and ranks #192 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Castleark Management held 63,950 shares of Cogent Biosciences worth $2.46M as of Q1 2026.
  • Cogent Biosciences was a new Castleark Management position in Q1 2026.
  • Cogent Biosciences made up 0.08% of Castleark Management's portfolio in Q1 2026, its #192 holding.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.